Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roussel Ronan, Darmon Patrice, Pichelin Matthieu, Goronflot Thomas, Abouleka Yawa, Ait Bachir Leila, Allix Ingrid, Ancelle Deborah, Barraud Sara, Bordier Lyse, Carlier Aurélie, Chevalier Nicolas, Coffin-Boutreux Christine, Cosson Emmanuel, Dorange Anne, Dupuy Olivier, Fontaine Pierre, Fremy Bénédicte, Galtier Florence, Germain Natacha, Guedj Anne-Marie, Larger Etienne, Laugier-Robiolle Stéphanie, Laviolle Bruno, Ludwig Lisa, Monier Arnaud, Montanier Nathanaëlle, Moulin Philippe, Moura Isabelle, Prevost Gaëtan, Reznik Yves, Sabbah Nadia, Saulnier Pierre-Jean, Serusclat Pierre, Vatier Camille, Wargny Matthieu, Hadjadj Samy, Gourdy Pierre, Cariou Bertrand, CORONADO investigators
Аннотация
MATERIALS AND METHODS: This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs. non-users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW).
RESULTS: Five hundred and ninety-six participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW-adjusted models showed no significant association between the use of DPP-4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77-1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death.
CONCLUSIONS: These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued.